SCIENTIFIC OPINION

Inability to assess the safety of riboflavin-enriched yeast added for nutritional purposes as a source of riboflavin in food supplements and the bioavailability of riboflavin from this source, based on the supporting dossier¹

Scientific Statement of the Panel on Food Additives and Nutrient Sources added to Food

(Question No EFSA-Q-2005-210)

Adopted on 5 June 2009

PANEL MEMBERS


¹ For citation purposes: Scientific Statement of the Panel on Food Additives and Nutrient Sources added to Food on the inability to assess the safety of riboflavin-enriched yeast added for nutritional purposes as a source of riboflavin in food supplements and the bioavailability of riboflavin from this source, based on the supporting dossier following a request from the European Commission. The EFSA Journal (2009) 1135, 1-6.
BACKGROUND AS PROVIDED BY THE COMMISSION

The European Community legislation lists nutritional substances that may be used for nutritional purposes in certain categories of foods as sources of certain nutrients.

The Commission has received a request for the evaluation of riboflavin-enriched yeast added for nutritional purposes to food supplements. The relevant Community legislative measure is:


TERMS OF REFERENCE AS PROVIDED BY THE COMMISSION

In accordance with Article 29 (1) (a) of Regulation (EC) No 178/2002, the European Commission asks the European Food Safety Authority to provide a scientific opinion, based on its consideration of the safety and bioavailability of riboflavin-enriched yeast added for nutritional purposes to food supplements.
STATEMENT

1. Introduction

Following a request from the European Commission to the European Food Safety Authority (EFSA), the Scientific Panel on Food Additives and Nutrient Sources added to Food (ANS) was asked to provide a scientific opinion on the safety of riboflavin-enriched yeast added for nutritional purposes as a source of riboflavin in food supplements and on the bioavailability of riboflavin from this source.

2. Summary of the information in the supporting dossier on riboflavin-enriched yeast

Riboflavin-enriched yeast is derived from cultures of specified strains of *Saccharomyces cerevisiae* grown in the presence of riboflavin. Fermentation takes place at a specified temperature and pressure for defined periods of time. This is followed by increasing the temperature to kill the yeast. The cell wall is ruptured enzymatically to release the contents which are then spray dried.

The petitioner has provided some general information on the manufacturing process, but no details on the procedures used to produce riboflavin-enriched yeast are provided.

According to the petitioner, riboflavin in riboflavin-enriched yeast is naturally integrated by the growing yeast into its own structure and occurs therefore, in the way riboflavin would be present in any food material.

The petitioner states that during fermentation in the presence of riboflavin, a specific strain of *Saccharomyces cerevisiae* incorporates riboflavin into ‘biological complexes’, the metabolic fate and the biological distribution of which are similar to those of other sources of riboflavin in the diet.

The petitioner states that “the integration will be chemically multi-formatted by the organism and therefore, its chemical name, formula, chemical family and CAS Registry Number is undefined”. Further details on the chemical characterisation of the fermentation products to demonstrate that the expected forms of riboflavin are present in the enriched yeast were not provided.

Comparative Fourier Transform Infrared (FTIR) spectra of the starter yeast, riboflavin, riboflavin-enriched yeast and a simple mixture of yeast and riboflavin have been provided.

Riboflavin-enriched yeast is described as a yellow amorphous hygroscopic powder with a yeast-like odour, soluble in water at 20°C.

According to the petitioner, riboflavin is present at 10% of the source. The remaining 90% is made up of enzymatically ruptured yeast cells.

The petitioner also provides microbiological specifications. Specifications for lead, mercury, cadmium and arsenic were not provided.

Specific proposals for use levels for riboflavin-enriched yeast were not provided. The petitioner only states that riboflavin-enriched yeast is currently used to provide between 1.65 mg riboflavin/day and up to a maximum of 5 mg riboflavin/day, depending on the type of supplement.
The petitioner states that no data on the bioavailability of riboflavin from riboflavin-enriched yeast are available. The petitioner only refers to a study by Vinson et al. (1989) who found 1.5 times more riboflavin in serum of rats fed a similar yeast-derived riboflavin material compared with riboflavin alone, suggesting better absorption from the diet.

No data on the safety of the source were provided.

3. Assessment

The Panel notes that *Saccharomyces cerevisiae* has a qualified presumption of safety (EFSA, 2008) but considers that this presumption of safety might not be applicable to the specific conditions of culture of the yeast in the presence of a high quantity of riboflavin.

According to the petitioner, fermentation in the presence of riboflavin within eukaryotic cells will produce riboflavin/yeast complexes similar to those of other sources of riboflavin in the diet.

According to the petitioner, from the comparative FTIR spectra it can be deduced that riboflavin is integrated in a ‘biological complex’ with yeast. The Panel considers that the FTIR spectra provided do not demonstrate the existence of such complexes.

The description of the manufacturing process used to produce riboflavin-enriched yeast was insufficient to characterise the product.

According to the petitioner, riboflavin from riboflavin-enriched yeast is safe. Although not explicitly stated in the dossier, the argument for the safety of riboflavin-enriched yeast appears to be based on riboflavin being a normal constituent of the diet, and the long history of use of *Saccharomyces cerevisiae* in fermented food and beverages. The assumption is that, provided there is no overload of normal metabolic pathways, fermentation within eukaryotic cells will produce riboflavin complexes, the metabolic fate and the biological distribution of which are similar to those of other sources of riboflavin in the diet.

The Panel notes that the petitioner has insufficiently chemically characterised the product.

The Panel also notes that it was not possible to assess the bioavailability of riboflavin from riboflavin-enriched yeast since neither data nor suitable supporting references were provided.

The Panel further notes that neither safety data nor suitable supporting references were provided to support the assumption of safety of riboflavin-enriched yeast.

**CONCLUSIONS**

The Panel concludes that due to the lack of an appropriate dossier supporting the use of riboflavin-enriched yeast in food supplements, the bioavailability of riboflavin from riboflavin-enriched yeast and the safety of riboflavin-enriched yeast cannot be assessed.

**Key words:**

Food supplements, riboflavin, vitamin B₂, yeast-transformed riboflavin, riboflavin-enriched yeast
REFERENCES


DOCUMENTATION PROVIDED TO EFSA


ACKNOWLEDGEMENTS

Inability to assess the safety of riboflavin-enriched yeast as a source of riboflavin in food supplements

**GLOSSARY / ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANS</td>
<td>Panel on Food Additives and Nutrient Sources added to Food</td>
</tr>
<tr>
<td>CAS</td>
<td>Chemical Abstracts Service</td>
</tr>
<tr>
<td>EC</td>
<td>European Commission</td>
</tr>
<tr>
<td>EFSA</td>
<td>European Food Safety Authority</td>
</tr>
<tr>
<td>FTIR</td>
<td>Fourier Transform Infrared</td>
</tr>
</tbody>
</table>